Navigation Links
New strategy to combat cystitis
Date:6/3/2011

Brussels - One in three women will be faced at least once in her life with cystitis, for some the start of a constantly recurring infection. Cystitis is caused by Escherichia coli bacteria which fasten on to the wall of the bladder by means of thread-like structures (pili). Han Remaut of the VIB Department for Structural Biology Brussels, Vrije Universiteit Brussel reveals for the first time the complex interactions which lead to the formation of these pili. This knowledge can be used to develop new antibiotics to treat infections of the urinary tract.

Cystitis

Around 80% of infections of the urinary tract are caused by the Escherichia coli bacteria, gram-negative rod-like bacteria. Although these bacteria form part of normal intestinal flora, virulent types can penetrate the bladder via the urethra and lead to urinary tract infections. These infections occur more often in women than in men and account for a large number of hospital-acquired infections, especially in the case of catheterized patients. Treatment consists of using existing antibiotics. However, the current generation of antibiotics is losing its power to fight these bacteria. Especially problematic are recurrent infections. There is an urgent need for new antibiotics.

Bacteria adhere to the cells of the urinary bladder

Bacteria can adhere to a surface due to their hair-like structures, known as pili or fimbriae. In the case of uropathogenic E. coli, type 1 pili occur which consist of four different sub-entities. The biosynthesis (formation) of these pili takes place through a conserved mechanism (the chaperone/usher biosynthesis route). As type 1 pili are responsible for the uropathogenic E. coli adhering to the host cells, these are promising targets for new antibacterials.

Structural biological techniques to investigate pili formation

Han Remaut, together with colleagues working for the Institute of Structural and Molecular Biology, University of London, is investigating the mechanism responsible for the biosynthesis of these pili. For this purpose, they are using X-ray diffraction - the standard technique for determining the structure of proteins. Detailed knowledge about the structure of proteins is necessary to gain an insight into how they function.

Han Remaut and colleagues were the first to successfully image the assembly complex leading to pili biosynthesis. Furthermore, this is also the first snapshot of a protein transporter in action.

New antibiotics for the treatment of infections of the urinary tract

This detailed knowledge about the biosynthesis of type 1 pili from E. coli can form the basis for the development of medicines which block the formation of the pili. If bacteria can no longer cling to the epithelial cells of the bladder, they will no longer be able to cause an infection. The mechanism responsible for E.coli attaching to the bladder is also used by other bacteria. As a result, this research can also contribute to the fight against other infectious diseases such as food poisoning or traveler's diarrhea.


'/>"/>

Contact: Joris Gansemans
info@vib.be
329-244-6611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related biology news :

1. Effects of anthropogenic sound on marine mammals -- a research strategy
2. GUMC researchers hone in on new strategy to treat common infection
3. Mitochondria could be a target for therapeutic strategy for Alzheimers disease patients
4. Hope for a rabies eradication strategy in Africa
5. RNA research strategy for Europe takes shape
6. Therapeutic hypothermia is promising strategy to minimize tissue damage
7. New therapeutic strategy could target toxic protein in most patients with Huntingtons disease
8. A combined tooth-venom arsenal revealed as key to Komodo dragons hunting strategy
9. New strategy for inhibiting virus replication
10. Science Coalition commends Presidents strategy for innovation
11. IEEE-USA President endorses national innovation strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2017)... 7, 2017   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... innovative, highly flexible and award winning eClinical solution, is ... iMedNet is a proven Software-as-a-Service (SaaS) clinical research ... (EDC), but also delivers an entire suite of eClinical ...
(Date:2/6/2017)... Feb. 6, 2017 According to Acuity ... driving border authorities to continue to embrace biometric ... are 2143 Automated Border Control (ABC) eGates and ... at more than 163 ports of entry across ... 2016 achieving a combined CAGR of 37%. APC ...
(Date:2/2/2017)... 2, 2017   TapImmune, Inc. (NASDAQ: ... specializing in the development of innovative peptide and ... cancer and metastatic disease, announced today it has ... of a second clinical lot of TPIV 200, ... alpha. The manufactured vaccine product will be used ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... clinical-stage oncology and dermatology biopharmaceutical company, today is ... in its previously announced rights offering of up ... common stock and Series C Convertible Preferred Stock ... As previously announced, the rights ...
(Date:2/24/2017)... Feb. 24, 2017 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced its unaudited financial results for the third quarter ... December 31, 2016. Third Quarter of Fiscal ... quarter of fiscal 2017 increased by 18.6% to RMB200.9 ...
(Date:2/24/2017)... , Feb. 24, 2017  OncoSec Medical Incorporated ... immunotherapies, will host a Key Opinion Leader event to ... an oral and poster presentation at the upcoming 2017 ... The KOL event will be held in-person and via ... EST / 9:00 AM PST at the Lotte New ...
(Date:2/23/2017)... 2017 /PRNewswire/ - The Fight Against Cancer Innovation Trust ... are pleased to report that Fusion Pharmaceuticals Inc. (Fusion) ... & Johnson Innovation – JJDC, Inc. (JJDC) as the ... TPG Biotechnology Partners, and Genesys Capital, as well as ... ...
Breaking Biology Technology: